Jove
Visualize
Contact Us

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

222
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
222
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K
Angina V: Nursing Management01:20

Angina V: Nursing Management

278
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
278
Angina II: Classification01:27

Angina II: Classification

308
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
308

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of angina pectoris: lessons from trials.

European heart journal·2026
Same author

Contrast-Derived Index of Microcirculatory Resistance (cIMR): A Novel Index for Measuring Coronary Microvascular Resistance.

Circulation. Cardiovascular interventions·2026
Same author

Intracoronary Imaging for the Management of Vulnerable Plaques.

Journal of clinical medicine·2026
Same author

Barriers preventing consideration of environmental risk factors by cardiologists.

European heart journal·2026
Same author

Non-invasive Coronary Functional Tests in Patients with Angina and Non-obstructive Coronary Artery Disease.

European cardiology·2026
Same author

Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.

Nature reviews. Cardiology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Device-Based Therapies for Refractory Angina.

Andrea Caffè1, Rocco A Montone1,2

  • 1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.

Journal of Clinical Medicine
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

Device-based therapies, like the Coronary Sinus Reducer (CSR), offer new hope for patients with persistent angina. While effective for symptom relief, further research is needed to fully understand their mechanisms and optimize outcomes.

Keywords:
Coronary Sinus Reducerchronic coronary syndromesdevice-based therapyenhanced external counter-pulsationextracorporeal shockwave myocardial revascularizationischemia with non-obstructive coronary arteries (INOCA)myocardial perfusion imagingrefractory anginaspinal cord stimulationstable angina

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K

Related Experiment Videos

Last Updated: Jan 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K

Area of Science:

  • Cardiology
  • Medical Devices
  • Ischemic Heart Disease

Background:

  • Many patients with ischemic heart disease experience persistent angina despite optimal medical therapy and revascularization.
  • This highlights a significant unmet need for novel and effective treatment strategies.

Purpose of the Study:

  • To review the current landscape of device-based therapies for angina.
  • To focus on the evidence supporting the Coronary Sinus Reducer (CSR) and other device interventions.
  • To discuss mechanisms, outcomes, and future research directions.

Main Methods:

  • Review of randomized trials and registries evaluating device-based therapies for angina.
  • Discussion of pathophysiological mechanisms and clinical outcomes.
  • Exploration of emerging device-based approaches.

Main Results:

  • The Coronary Sinus Reducer (CSR) shows promise, improving angina symptoms and quality of life with a good safety profile.
  • A disconnect exists between symptomatic relief and objective measures of myocardial perfusion, indicating incompletely understood mechanisms.
  • Other devices like enhanced external counterpulsation, neuromodulation, and shockwave therapy are also under investigation.

Conclusions:

  • Device-based therapies represent a developing frontier in angina management.
  • Integrating patient-reported outcomes with physiological and imaging assessments is crucial for refining indications and improving long-term results.
  • These therapies hold potential for improving outcomes in patients with refractory angina.